Search results
Your search for TFRC returned no results
Showing 1901 to 1950 of 2467 results for term
Showing 1901 to 1950 of 2467 results for term
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
the NICE website on behalf of the publishers and under specific licensing terms with both parties. They are not provided through the...
Curos for preventing infections when using needleless connectors (HTG510)
Evidence-based recommendations on Curos for preventing infections when using needleless connectors.
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
Emergency and acute medical care in over 16s: service delivery and organisation (NG94)
This guideline covers organising and delivering emergency and acute medical care for people aged over 16 in the community and in hospital. It aims to reduce the need for hospital admissions by giving advanced training to paramedics and providing community alternatives to hospital care. It also promotes good-quality care in hospital and joint working between health and social services.
Physical activity: for NHS staff, patients and carers (QS84)
This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS84Show all sections
Sections for QS84
- Quality statements
- Quality statement 1: Advice for adults during NHS Health Checks
- Quality statement 2: Advice for parents or carers as part of the Healthy Child Programme 2-year review
- Quality statement 3: Advice for parents or carers as part of the National Child Measurement Programme
- Quality statement 4: Implementing a physical activity programme for employees in NHS organisations
- Update information
- About this quality standard
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
health threat, raising awareness is a first step in reducing the risk of long-term health issues, especially for vulnerable groups.In...
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
Hypothermia: prevention and management in adults having surgery (CG65)
This guideline covers preventing and managing inadvertent hypothermia in people aged 18 and over having surgery. It offers advice on assessing patients’ risk of hypothermia, measuring and monitoring temperature, and devices for keeping patients warm before, during and after surgery.
Permission to use NICE content for artificial intelligence (AI) purposes
and a fee (for international use). AI requests are not covered by the terms of the NICE UK Open Content Licence . NICE content cannot be...
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
non-muscle-invasive bladder cancer, are these follow-up regimens equally effective in terms of identification of progression, cost...
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
This guideline covers alcohol problems among people over 10. It aims to prevent and identify such problems as early as possible using a mix of policy and practice.
Urinary tract infection (lower): antimicrobial prescribing (NG109)
This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
Suture fixation of acute disruption of the distal tibiofibular syndesmosis (HTG374)
Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)
Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)
Evidence-based recommendations on delgocitinib (Anzupgo) for treating moderate to severe chronic hand eczema in adults when topical corticosteroids have not worked or are not suitable.
Total prosthetic replacement of the temporomandibular joint (HTG352)
Evidence-based recommendations on total prosthetic replacement of the temporomandibular joint. This involves replacing the joint with an artificial one.
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults.
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
This quality standard has been withdrawn. Specialist neonatal care is covered in the NICE quality standards for specialist neonatal respiratory care for babies born pre-term, developmental follow-up of children and young people born preterm, maternal and child nutrition and postnatal care.
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
Read NICE's statement on modern slavery and human trafficking.
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
reported outcome measures, functional outcomes, time to recovery and long-term outcomes (12 months to 18 months). Any explanatory...
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .